• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·COLINZ.BO
Share

Colinz Laboratories Limited Stocks

₹ 74.7Last Updated 21.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₹ 1.87M

₹ 74.7
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Colinz Laboratories Ltd. specializes in producing a diverse range of pharmaceutical formulations, available in various dosage forms such as tablets, capsules, granules, oral liquids, injectables, ointments, and creams. The company's offerings target therapeutic areas including gynecology, cardiology, and gastroenterology, and span product categories like allopathy, ayurvedics, and nutraceuticals. Established on October 6, 1986, Colinz Laboratories is based in Mumbai, India.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 02:52

Anthropic has released a new, cost-effective AI model. How did the creator of ChatGPT respond?

23.09.2026 01:36

The Nasdaq closed at a record high for the second day in a row. Oil prices fell to a two-week low.

23.09.2026 00:34

Meta Has Created a "Killer Product": What Wall Street Is Saying About the New AI Assistant, Muse

22.09.2026 23:28

Trump at the UN: The U.S. Must Either Reach an Agreement on Iran's Nuclear Program or "Send Them to Hell"

22.09.2026 22:47

"Bad Guys" Had Their Accounts Closed: Standard Chartered Responds to Article on Sanctions Evasion

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026